CA2725257A1 - Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation - Google Patents

Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation Download PDF

Info

Publication number
CA2725257A1
CA2725257A1 CA2725257A CA2725257A CA2725257A1 CA 2725257 A1 CA2725257 A1 CA 2725257A1 CA 2725257 A CA2725257 A CA 2725257A CA 2725257 A CA2725257 A CA 2725257A CA 2725257 A1 CA2725257 A1 CA 2725257A1
Authority
CA
Canada
Prior art keywords
sialylation
alpha
fsh
rfsh
recombinant fsh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2725257A
Other languages
English (en)
French (fr)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring International Center SA
Original Assignee
Ferring International Center SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2725257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring International Center SA filed Critical Ferring International Center SA
Publication of CA2725257A1 publication Critical patent/CA2725257A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2725257A 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation Pending CA2725257A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528.9 2008-04-25
EP08251528 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
CA2725257A1 true CA2725257A1 (en) 2009-10-22

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2725257A Pending CA2725257A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Country Status (29)

Country Link
US (6) US8951967B2 (https=)
EP (7) EP3045471B1 (https=)
JP (7) JP2011519359A (https=)
KR (5) KR20160056960A (https=)
CN (3) CN105906703A (https=)
AR (1) AR071479A1 (https=)
AU (5) AU2009237479B2 (https=)
BR (1) BRPI0910461B8 (https=)
CA (1) CA2725257A1 (https=)
CY (1) CY1115413T1 (https=)
DK (6) DK2808340T3 (https=)
ES (5) ES2468318T3 (https=)
FI (4) FI3098234T3 (https=)
FR (3) FR17C1020I2 (https=)
HR (5) HRP20140535T1 (https=)
HU (9) HUE068565T2 (https=)
IL (2) IL208538A (https=)
LT (8) LT2808340T (https=)
MX (3) MX355457B (https=)
NO (4) NO2017025I1 (https=)
NZ (1) NZ588381A (https=)
PL (6) PL3144318T3 (https=)
PT (6) PT3045471T (https=)
RU (3) RU2682270C2 (https=)
SA (1) SA109300228B1 (https=)
SI (6) SI2268666T1 (https=)
TW (1) TWI488640B (https=)
WO (1) WO2009127826A1 (https=)
ZA (1) ZA201007373B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
PT2621517E (pt) 2010-09-29 2015-10-16 Ferring Bv Composição para uso no tratamento da infertilidade
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
PL2691119T3 (pl) 2011-03-31 2019-01-31 Ferring B.V. Preparat farmaceutyczny
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
WO2016102436A1 (en) * 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
EP3283097B1 (en) 2015-04-17 2020-02-12 Ferring B.V. Fsh for treatment of infertility
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
MX2020002235A (es) 2017-09-01 2020-07-20 Ferring Bv Composicion para la estimulacion ovarica controlada.
HUE071268T2 (hu) 2018-04-30 2025-08-28 Ferring Bv Készítmény szabályozott petefészek-stimuláláshoz
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
KR20240167660A (ko) 2022-04-01 2024-11-27 훼링 비.브이. 불임의 치료를 위한 혼합 프로토콜
AU2023275943A1 (en) 2022-05-26 2024-10-17 Ferring B.V. Compositions and methods for treatment of infertility in males
KR20250033230A (ko) 2022-07-08 2025-03-07 훼링 비.브이. 자궁내 인공수정(iui)을 위한 조성물 및 방법
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
PT1176976E (pt) 1999-05-07 2006-11-30 Applied Research Systems Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
PT1465987E (pt) 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
PT2621517E (pt) 2010-09-29 2015-10-16 Ferring Bv Composição para uso no tratamento da infertilidade
PL2691119T3 (pl) 2011-03-31 2019-01-31 Ferring B.V. Preparat farmaceutyczny
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
MX2016013449A (es) 2014-04-18 2017-05-04 Glycotope Gmbh Hiperestimulacion ovarica controlada con la hormona estimuladora folicular humana recombinante mejorada.

Also Published As

Publication number Publication date
KR20190092608A (ko) 2019-08-07
EP2268666B1 (en) 2014-03-12
US20240327487A1 (en) 2024-10-03
RU2682270C2 (ru) 2019-03-18
AU2017225020B2 (en) 2019-11-14
HRP20241187T1 (hr) 2024-12-06
AU2014203277C1 (en) 2017-07-27
HUS1700025I1 (hu) 2017-06-28
RU2014141994A3 (https=) 2018-05-28
US11952407B2 (en) 2024-04-09
JP2018021037A (ja) 2018-02-08
DK4015527T3 (da) 2025-04-14
CN105906703A (zh) 2016-08-31
ES2989729T3 (es) 2024-11-27
IL230571A (en) 2015-11-30
US9546204B2 (en) 2017-01-17
JP2020040956A (ja) 2020-03-19
AU2009237479A1 (en) 2009-10-22
HUS1700036I1 (hu) 2017-10-30
RU2014141994A (ru) 2016-05-10
PT3098234T (pt) 2024-10-21
ES2629392T3 (es) 2017-08-09
ES3023526T3 (en) 2025-06-02
RU2537268C2 (ru) 2014-12-27
SI3045471T1 (sl) 2017-07-31
BRPI0910461A2 (pt) 2018-03-27
AU2017225020A1 (en) 2017-09-28
PT2268666E (pt) 2014-06-25
US20150065695A1 (en) 2015-03-05
LT2808340T (lt) 2016-11-10
CY1115413T1 (el) 2017-01-04
IL208538A (en) 2014-03-31
US20110105398A1 (en) 2011-05-05
SI3144318T1 (sl) 2020-12-31
PT2808340T (pt) 2016-11-21
AU2009237479B2 (en) 2014-05-15
CN102066414A (zh) 2011-05-18
DK3045471T3 (en) 2017-06-26
US20180079794A1 (en) 2018-03-22
FR17C1020I2 (fr) 2020-04-10
HRP20250313T1 (hr) 2025-05-09
US9771407B2 (en) 2017-09-26
EP3144318A1 (en) 2017-03-22
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
MX348622B (es) 2017-06-22
US20160347811A1 (en) 2016-12-01
US8951967B2 (en) 2015-02-10
EP2268666A1 (en) 2011-01-05
RU2745557C1 (ru) 2021-03-29
LT3045471T (lt) 2017-07-10
HUE068565T2 (hu) 2025-01-28
PT4015527T (pt) 2025-04-10
RU2745557C3 (ru) 2021-12-10
JP2017060476A (ja) 2017-03-30
AU2014203277A1 (en) 2014-07-24
SI4015527T1 (sl) 2025-05-30
FIC20250025I1 (fi) 2025-07-11
EP3045471B1 (en) 2017-03-29
DK2808340T3 (en) 2016-12-05
LT4015527T (lt) 2025-04-10
SI2808340T1 (sl) 2016-12-30
KR20170110741A (ko) 2017-10-11
KR102108377B1 (ko) 2020-05-08
HRP20161520T1 (hr) 2016-12-30
AU2017204258A1 (en) 2017-07-20
EP3045471A1 (en) 2016-07-20
EP3098234B1 (en) 2024-07-31
DK2268666T3 (da) 2014-05-12
NO2017050I1 (no) 2017-09-28
LTPA2025525I1 (https=) 2025-07-25
PL3098234T3 (pl) 2025-01-07
PT3045471T (pt) 2017-06-14
KR101622944B1 (ko) 2016-05-23
LTPA2017018I1 (lt) 2017-06-26
KR20180095140A (ko) 2018-08-24
FR25C1003I1 (fr) 2025-02-28
AU2017204259A1 (en) 2017-07-20
AU2014203277B2 (en) 2017-04-06
EP2808340B1 (en) 2016-08-17
CN105906702A (zh) 2016-08-31
JP2015120696A (ja) 2015-07-02
ZA201007373B (en) 2011-06-29
HK1199039A1 (en) 2015-06-19
JP6762916B2 (ja) 2020-09-30
NO2025032I1 (no) 2025-07-14
DK3098234T3 (da) 2024-10-21
PL2268666T3 (pl) 2014-08-29
JP2022031652A (ja) 2022-02-22
HUE030652T4 (en) 2017-09-28
EP3098234A1 (en) 2016-11-30
HUE030652T2 (en) 2017-05-29
US12516094B2 (en) 2026-01-06
SI3098234T1 (sl) 2024-10-30
EP2808340A1 (en) 2014-12-03
TWI488640B (zh) 2015-06-21
RU2010141908A (ru) 2012-05-27
PL2808340T3 (pl) 2017-02-28
NZ588381A (en) 2012-05-25
DK3144318T3 (da) 2020-12-07
EP2722339A1 (en) 2014-04-23
FI3098234T3 (fi) 2024-10-31
BRPI0910461B8 (pt) 2021-05-25
JP7316905B2 (ja) 2023-07-28
ES2610277T3 (es) 2017-04-26
HK1146284A1 (en) 2011-05-20
AU2017204258B2 (en) 2017-08-17
EP4015527A1 (en) 2022-06-22
PL3045471T3 (pl) 2017-10-31
PL3144318T3 (pl) 2021-02-08
JP2024038000A (ja) 2024-03-19
FR17C1020I1 (https=) 2020-04-10
HUE033830T2 (en) 2018-01-29
EP3144318B1 (en) 2020-09-23
LTPA2025505I1 (https=) 2025-02-10
JP2011519359A (ja) 2011-07-07
TW200948378A (en) 2009-12-01
KR20160056960A (ko) 2016-05-20
US10995128B2 (en) 2021-05-04
WO2009127826A1 (en) 2009-10-22
AR071479A1 (es) 2010-06-23
HRP20170958T1 (hr) 2017-09-22
HRP20140535T1 (hr) 2014-07-18
JP6486310B2 (ja) 2019-03-20
KR20110005863A (ko) 2011-01-19
NO2017025I1 (no) 2017-06-06
HUS2500029I1 (hu) 2025-07-28
BRPI0910461A8 (pt) 2018-10-16
FIC20250003I1 (fi) 2025-01-15
FI4015527T3 (fi) 2025-04-29
HUS2500008I1 (hu) 2025-02-28
EP4015527B1 (en) 2025-01-22
MX355457B (es) 2018-04-19
SA109300228B1 (ar) 2014-04-08
NO2025006I1 (no) 2025-01-16
PT3144318T (pt) 2020-11-04
ES2468318T3 (es) 2014-06-16
BRPI0910461B1 (pt) 2021-02-23
FR25C1025I1 (fr) 2025-09-19
HUE071059T2 (hu) 2025-07-28
SI2268666T1 (sl) 2014-07-31
AU2017204259B2 (en) 2017-08-17
IL208538A0 (en) 2010-12-30
HUS1700024I1 (hu) 2017-06-28
LT3098234T (lt) 2024-09-10
US20210332099A1 (en) 2021-10-28
LTPA2017029I1 (lt) 2017-10-10

Similar Documents

Publication Publication Date Title
US11952407B2 (en) Pharmaceutical preparation
HK40068781B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK40068781A (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1233276B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1233276A1 (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227049B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227049A1 (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1199039B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1146284B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1197825A (en) Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation
HK1227046B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227046A1 (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20120614

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241011

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250408

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250408

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20251008

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251009

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251029

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251029

C13 Application revived following an application revival request

Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260317

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260407